Tyra Biosciences to Host Conference Call on Initial Results of Oral Dabogratinib from the SURF302 Phase 2 Study for IR NMIBC on September 9, 2026

Tyra Biosciences (TYRA) will host a conference call and webcast on September 9, 2026 at 8:00 am ET to discuss initial clinical results from the SURF302 Phase 2 study of oral dabogratinib in intermediate risk non-muscle invasive bladder cancer (IR NMIBC).

Rhea-AI Summary

Tyra Biosciences (TYRA) will host a conference call and webcast on September 9, 2026 at 8:00 am ET to discuss initial clinical results from the SURF302 Phase 2 study of oral dabogratinib in intermediate risk non-muscle invasive bladder cancer (IR NMIBC).

Investors can access the live webcast and slides via the “For Investors” page on the company’s website, or register in advance for telephone participation. A replay will be available online for at least 90 days.

Market Context

ANAB was up 1.0964148677885532% in the current momentum scanner. That isolated peer move offered no ...

Analysis

ANAB was up 1.0964148677885532% in the current momentum scanner. That isolated peer move offered no multi-peer confirmation; the announcement scheduled, rather than disclosed, initial SURF302 data, leaving data quality and interpretation as key watchpoints.

Key Figures

Trial phase: Phase 2 Conference date: September 9, 2026 Call time: 8:00 am ET +1 more

4 metrics

Trial phase Phase 2 SURF302 study

Conference date September 9, 2026 Initial clinical-results call

Call time 8:00 am ET September 9, 2026

Replay availability 90 days Minimum website archive period

Previous Conferences,clinical trial Reports

1 past event · Latest: Oct 23 (Neutral)

Same Type Pattern 1 events

Date	Event	Sentiment	24h Move	Catalyst
Oct 23	Clinical data call	Neutral	+1.3%	Conference call scheduled to present interim SURF301 Phase 1/2 clinical results

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Pattern Detected

The tag-specific prior clinical-data call was followed by a 1.31% 24-hour gain, providing one comparable observation.

Key Terms

fgfr, nmibc

2 terms

fgfr medical

"Fibroblast Growth Factor Receptor (FGFR) biology"

FGFR (fibroblast growth factor receptor) is a family of cell-surface proteins that bind growth factors and send signals telling cells to grow, divide, or move. Mutations or abnormal activity in FGFRs can drive certain cancers or other diseases, making them common targets for drugs and diagnostic tests. For investors, FGFR status matters because it can determine whether a drug candidate targets a clear biological mechanism, affects clinical trial design, or supports companion diagnostics and market opportunity.

nmibc medical

"intermediate risk non-muscle invasive bladder cancer (IR NMIBC)"

A common form of bladder cancer that stays confined to the bladder’s inner lining or the layer just below it and has not grown into the deeper muscle wall. It matters to investors because it often requires repeated procedures, ongoing surveillance and long-term treatments, creating a sizable and stable market for diagnostics, drugs and medical devices; think of it like a surface-level problem that needs frequent check-ups and follow-up care rather than a one-time fix.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

CARLSBAD, Calif., Sept. 4, 2026 /PRNewswire/ -- Tyra Biosciences, Inc. (Nasdaq: TYRA), a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large opportunities in Fibroblast Growth Factor Receptor (FGFR) biology, today announced that it will host a conference call and webcast on Wednesday, September 9, 2026 at 8:00 am ET to discuss initial clinical results from the SURF302 Phase 2 study evaluating oral dabogratinib for intermediate risk non-muscle invasive bladder cancer (IR NMIBC).

Conference Call and Webcast Information

TYRA is hosting a conference call and webcast on September 9, 2026, at 8:00 am ET. Participants may access a live webcast of the call and the associated slide presentation on the "For Investors" page of the TYRA website at https://ir.tyra.bio. To participate via telephone, please register in advance at this link. Upon registration, all telephone participants will receive a confirmation email detailing how to join the conference call, including the dial-in number along with a unique passcode and registrant ID that can be used to access the call. A replay of the conference call and webcast will be archived on the Company's website for at least 90 days.

About Tyra Biosciences

Tyra Biosciences, Inc. (Nasdaq: TYRA) is a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large opportunities in FGFR biology. TYRA's in-house precision medicine platform, SNÅP, enables rapid and precise drug design through iterative molecular SNÅPshots that help TYRA design and predict which candidates may demonstrate the highest potency, selectivity and tolerability in the clinic. TYRA's expertise in FGFR biology has created a differentiated pipeline with clinical-stage programs in targeted oncology and genetically defined conditions. TYRA's lead precision medicine stemming from SNÅP, oral dabogratinib, is a potential first-in-class selective FGFR3 inhibitor in development for LG-UTUC, IR NMIBC and ACH. TYRA is also developing TYRA-430, an oral, investigational FGFR4/3-biased inhibitor for FGF19+/FGFR4-driven cancers, in the SURF431 study for advanced hepatocellular carcinoma, and TYRA-200, an oral, investigational FGFR1/2/3 inhibitor, in the SURF201 study for metastatic intrahepatic cholangiocarcinoma. TYRA is based in Carlsbad, California. For more information, please visit www.tyra.bio and engage with TYRA on LinkedIn.

Contact
Amy Conrad
aconrad@tyra.bio

 

View original content to download multimedia:https://www.prnewswire.com/news-releases/tyra-biosciences-to-host-conference-call-on-initial-results-of-oral-dabogratinib-from-the-surf302-phase-2-study-for-ir-nmibc-on-september-9-2026-302870004.html

SOURCE Tyra Biosciences

FAQ

When is Tyra Biosciences (TYRA) holding the SURF302 Phase 2 results conference call?

The conference call and webcast to discuss initial results from the SURF302 Phase 2 study are scheduled for Wednesday, September 9, 2026 at 8:00 am ET. The company will review early clinical data for oral dabogratinib in IR NMIBC.

What study results will be discussed on Tyra Biosciences’ September 9, 2026 TYRA conference call?

The call will cover initial clinical results from the SURF302 Phase 2 study, which evaluates oral dabogratinib for patients with intermediate risk non-muscle invasive bladder cancer (IR NMIBC).

How can investors access the Tyra Biosciences (TYRA) SURF302 results webcast?

Investors can access a live webcast of the call and the associated slide presentation on the “For Investors” page of the Tyra Biosciences website at https://ir.tyra.bio.

How do I join the Tyra Biosciences (TYRA) SURF302 conference call by telephone?

To participate via telephone, investors must register in advance using the provided registration link. After registering, they receive a confirmation email containing the dial-in number, a unique passcode, and a registrant ID needed to access the call.

Will a replay of the Tyra Biosciences (TYRA) SURF302 Phase 2 results call be available?

Yes. A replay of the conference call and webcast will be archived on the company’s website for at least 90 days, allowing investors to review the presentation after the live event.